It is expected that these new core αDG antibodies will be useful in furthering the understanding of dystroglycanopathies and other dystroglycan-linked pathologies. This evidence concerns the gene DAG1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.